22157.jpg
Insights on the Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Global Market to 2030 - by Scale of Operation, Type of Vector, Application Area, Therapeutic Area and Regions
August 13, 2021 04:13 ET | Research and Markets
Dublin, Aug. 13, 2021 (GLOBE NEWSWIRE) -- The "Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, and...
22157.jpg
Global Gene Therapy Market 2021-2027 - COVID-19 Causes Gene Therapy Market to Buckle & Collapse
July 13, 2021 03:28 ET | Research and Markets
Dublin, July 13, 2021 (GLOBE NEWSWIRE) -- The "Gene Therapy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global market for Gene Therapy...
22157.jpg
Global Gene Therapy Market Report 2021-2025 & 2030: Market is Expected to Reach $12.16 Billion in 2025 at a CAGR of 32%
June 28, 2021 04:38 ET | Research and Markets
Dublin, June 28, 2021 (GLOBE NEWSWIRE) -- The "Gene Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The global...
22157.jpg
Global Gene Therapy Market Report 2020-2027: Market is Projected to Reach a Revised $3.3 Billion
November 27, 2020 04:18 ET | Research and Markets
Dublin, Nov. 27, 2020 (GLOBE NEWSWIRE) -- The "Gene Therapy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. In a Major Setback to the...
GeneticTechnologies-Logo-SmallUse-RGB.jpg
Genetic Technologies Announces US Sales Have Commenced via Online Health Platform
September 11, 2020 08:33 ET | Genetic Technologies Ltd
MELBOURNE, Australia, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”) is delighted to announce that initial sales of its...
US Patent Office Grants Key Risk Test Patent
June 18, 2020 08:00 ET | Genetic Technologies Ltd
Issuance of US Patent No: US 10,683,549, Methods for assessing risk of developing breast cancer.Filed provisional patent for its COVID-19 Severity Risk Test, 2020901739 – Methods of assessing risk...
CONTEMPORARY OBSTETRICS AND GYNECOLOGY OF DAYTON ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
September 30, 2013 10:34 ET | Genetic Technologies Group
DAYTON, Ohio, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Contemporary Obstetrics & Gynecology, part of the Providence Medical Group, today announced the availability of the BREVAGen™ predictive risk...
PEARL W. YEE, M.D. INC. OF SAN FRANCISCO ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
September 16, 2013 10:08 ET | Genetic Technologies Group
SAN FRANCISCO, Sept. 16, 2013 (GLOBE NEWSWIRE) -- Pearl Yee, MD, FACOG and clinical professor at the University of California, San Francisco, is pleased to announce that her private practice, Pearl W....
OB/GYN ASSOCIATES IN LEWISBURG, PA ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
August 26, 2013 13:06 ET | Genetic Technologies Group
SUNBURY, PA., Aug. 26, 2013 (GLOBE NEWSWIRE) -- Russell Stankiewicz, MD, FACOG, CCD, NMCP, is pleased to announce that OB/GYN Associates of Lewisburg, P.C. in Lewisburg, PA is now offering the...
THE HEWITT CENTER FOR BREAST WELLNESS AT GRIFFIN HOSPITAL IN DERBY, CT LAUNCHES HIGH-RISK PROGRAM INCLUDING STATE-OF-THE-ART BREAST CANCER SCREENING OPTIONS
June 24, 2013 12:16 ET | Genetic Technologies Group
DERBY, Conn., June 24, 2013 (GLOBE NEWSWIRE) -- Denise Barajas, MD, medical director at The Hewitt Center for Breast Wellness in Derby, CT, has launched a high-risk breast cancer program that includes...